Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Omniox Inc. maintains a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, there are 2 pending office actions in the portfolio. These actions are assigned to 2 distinct examiners and are located in 2 distinct art units, showing a distributed prosecution landscape.
The busiest examiner for the portfolio is CORDAS, EMILY ANN, who is responsible for 1 pending office action. With 2 pending office actions total and 2 distinct examiners, the current workload is divided equally. The involvement of 2 distinct art units indicates that the company's biotechnology applications are being processed across different specialized groups within the patent office. For the company, this means that its 2 pending office actions are subject to the different examination standards and technical focuses of 2 distinct art units and 2 different examiners. Managing 2 distinct examiners in 2 different art units for only 2 pending actions indicates a highly fragmented prosecution landscape for the company's current biotechnology filings.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CORDAS, EMILY ANN | 1 | 51.0% | +57.3% |
| FISCHER, JOSEPH | 1 | 43.4% | +45.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684586 | H-NOX PROTEINS FOR ORGAN PRESERVATION | CORDAS, EMILY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18308203 | MODULATION OF HYPOXIA ASSOCIATED WITH STROKE | FISCHER, JOSEPH | 71d |
| 18684586 | H-NOX PROTEINS FOR ORGAN PRESERVATION | CORDAS, EMILY ANN | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684586 | H-NOX PROTEINS FOR ORGAN PRESERVATION | CORDAS, EMILY ANN | 1632 | §102§103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18308203 | MODULATION OF HYPOXIA ASSOCIATED WITH STROKE | FISCHER, JOSEPH | 1658 | §103Other | Final Rejection | 71d | Pending | Apr 27, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOmniox Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Emily Ann Cordas has the most, with 1 of Omniox Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.